Ulrich Jaeger

Ulrich Jaeger is an expert in Hematology at Asklepios (Group) (Germany). As of October 2026, ScienceLeadR ranks Ulrich Jaeger in the top 1% of experts worldwide for Lymphoma, Lymphoproliferative Disorders and Leukemia. Ulrich Jaeger has authored 759 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 1 of them ongoing. SLR score: 2,317 (community average: 125). How the SLR is computed.

Hematology

Subspecialties: Immunology - Oncology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 28, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1990 - 2026

Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 759

Citations

Citations: 36 101 1st author: 59 Last author: 114 Unique author: 11

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study. PMID 42933440 — cells, disease-free survival, lymphoma, b-cell, lymphoma, neoplasms, oxaliplatin, drug-related side effects and adverse reactions, rituximab, therapeutics, t-lymphocytes, veins, b-lymphocytes, transplantation, car-t cell	Lancet Oncol Top journal	2026	0
Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists. PMID 42842182 — cells, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, neoplasms, drug therapy, tumor burden, histology, diagnosis, therapeutics, b-lymphocytes, prognosis, receptors, antigen, t-cell	Adv Ther	2026	0
The relationship between childhood maltreatment and narcissistic dimensions across healthy and clinical populations. PMID 42485789 — patient health questionnaire, child abuse	Child Abuse Negl	2026	1
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL. PMID 42462111 — safety, immunoglobulins, therapeutics	Blood	2026	1
DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia. PMID 42200459 — cells, leukemia, hairy cell, neoplasms, leukemia, cladribine, diagnosis, therapeutics, mutation, hematologic diseases	Blood Adv	2026	0

Clinical Studies 29

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 13

Phase 2 8

N/A 4

Phase 1 3

Phase 1/Phase 2 1

By status:

Completed 23

Active not recruiting 3

Recruiting 1

Terminated 1

Unknown 1

By type:

Interventional 25

Observational 4

By Monocentric/Multicentric:

monocentric 6

multicentric2to4 0

multicentric5to9 2

multicentricup10 21

Main Topics

Hemic and Lymphatic Diseases 27

Immune System Diseases 26

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Efficacy and Safety of MB CART2019 1 vs SoC in Lymphoma Patients NCT04844866 — cells, lymphoma, follicular, safety, blood, hodgkin disease, lymphoma, b-cell, hematologic neoplasms, lymphoma, lymphoma, large b-cell, diffuse, neoplasms, multiple chronic conditions, leukapheresis, oxaliplatin, rituximab, receptors, antigen, receptors, chimeric antigen, lymphoma, non-hodgkin, therapeutics, bendamustine hydrochloride, b-lymphocytes, car-t cell	Phase 2	Recruiting	2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice